Dermata Therapeutics

Transforming Topical Treatment of the Skin

Corporate Presentation
2025

FORWARD LOOKING STATEMENTS AND DISCLAIMERS

This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our current and future financial performance, business plans and objectives, current and future clinical and preclinical development activities, timing and success of our ongoing and planned clinical trials and related data, the timing of announcements, updates and results of our clinical trials and related data, our ability to obtain and maintain regulatory approval, the potential therapeutic benefits and economic value of our product candidates, competitive position, industry environment and potential market opportunities. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” and similar expressions are intended to identify forward looking statements.

Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but not limited to, those related to the success, cost and timing of our product candidate development activities and ongoing and planned clinical trials; our plans to develop and commercialize targeted therapeutics, including our lead product candidates Xyngari and DMT410; the progress of patient enrollment and dosing in our clinical trials; the ability of our product candidates to achieve applicable endpoints in the clinical trials; the safety profile of our product candidates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations, development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates, and our ability to serve those markets; our commercialization, marketing and manufacturing capabilities and strategy; future agreements with third parties in connection with the commercialization of our product candidates; our expectations regarding our ability to obtain and maintain intellectual property protection; our dependence on third party manufacturers; the success of competing therapies that are or may become available; our ability to attract and retain key scientific or management personnel; our ability to identify additional product candidates with significant commercial potential consistent with our commercial objectives; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.

We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. Moreover, we operate in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Although our management believes that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur. We undertake no obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

PROPRIETARY INFORMATION

Corporate Highlights

Unique, multi-use topical platform technology utilizing multiple mechanisms of actions

Pipeline addressing **large medical and aesthetic dermatology** market opportunities

Lead program with **compelling Phase 2b clinical data** for once-weekly topical treatment of acne





Xyngari

Acne – STAR-1 Phase 3 – Statistically Significant

- Once-weekly topical application
- Positive STAR-1 Phase 3 study
- STAR-2 Phase 3 study to begin in 2025

Psoriasis – Positive Phase 1b Completed

- Inhibits inflammatory cytokines IL-17A & IL-17F *in vitro*
- Reduced lesion size after 8 weeks

DMT410

Hyperhidrosis – Phase 2a planned with DAXXIFY

- Phase 1 POC completed with BOTOX
- Topical delivery of botulinum toxin to the dermis
- 75% reduction in gravimetric sweat production

Aesthetics – Phase 1b PoC Completed

- Clinical improvement in aesthetic appearance seen
  - Pore Size
  - Fine Lines
  - Melasma
  - Sebum production

dermata

Experienced Management Team and Board

Senior Management

Gerry Proehl
Chairman, President, and CEO

Kyri Van Hoose, C.P.A., MBA
SVP, Chief Financial Officer

Maria Bedoya Toro Munera, Ph.D.
SVP, Regulatory Affairs & Quality Assurance

Chris Nardo, M.P.H., Ph.D.
SVP, Chief Development Officer

Board of Directors

Gerry Proehl
dermata

Wendell Wierenga Ph.D.
SANTARUS, INC.

Steven J. Mento, Ph.D.
Histogen

Andrew Sandler, M.D.
ALPINE Immune Sciences

David Hale
Hale BioPharma Ventures, LLC.

Kathleen Scott
ARS PHARMA

Mary Fischer
colorescience

Brittany Bradrick
NEURELIS

Market Opportunities in Dermatology

	Xyngari/DMT410 – Acne	DMT410 - Aesthetics	DMT410 – Hyperhidrosis
US Prevalence	**~50M**	**~13.1M (procedures)**	**~2M (diagnosed)**
Market Size	**~$2.3B[2]**	**~$12B[5]**	**~$281M[4]**
Opportunity Highlights	85% of teenagers experience some form of acne[1] Few new novel topical treatment options • **Most new products are reformulations and dosed QD or BID**	Almost 9.5 million procedures with neuromodulators[3] • Average cost of one session is $435[3] • Untapped markets where neuromodulators are rarely used	BOTOX® injections expected to be **40%** of the overall market. **Growing demand for hyperhidrosis treatments**, especially with increasing disease awareness

dermata

1 – Guideline for Care and Management of Acne
2 – IQVIA, Inc. Top Line Market and Sales Analysis from years 2015-2020
3 – 2023 Plastic Surgery Statistics Report
4 – GlobalData Axillary Hyperhidrosis: opportunity Assessment and Forecast to 2030
5– Stifl Dermatology Healthcare Market Overview

Unique Natural Platform Technology with Dual MoA

Spongilla-derived Platform

- Complex freshwater sponge, *Spongilla lacustris*, contains unique characteristics, optimized for clinical applications
- Possesses multiple complementary chemical and mechanical properties to potentially enhance pharmaceutical treatment effect
- Potential for use as a standalone product for needle-free topical application of large molecules for intradermal delivery



Mechanism of Actions

Chemical Components: contains chemical compounds that demonstrated *in vitro*:

- Anti-inflammatory activity:
  - Reduction of C. *acnes* stimulated IL-8 production in NHEK
  - Inhibition of IL-17A and IL-17F expression in human cell lines
- Anti-microbial activity against C. *acnes*
- Effects on sebum production, namely inhibition of lipogenesis in sebocytes

Mechanical Component: uniquely sized siliceous spicules that exfoliate the dermal epithelium:

- Creating microchannels into the dermis
- Opening closed comedones (blackheads)
- Promoting collagen production

dermata

Xyngari

Once Weekly Topical Treatment

Xyngari Benefits

Frequency of Treatments

- Current topical treatments require one or two applications daily, resulting in poor compliance and early discontinuation
- **Once weekly application of Xyngari may optimize compliance**

Time to Treatment Effect

- Current topical treatments may take 6-8 weeks before a patient perceives treatment effect
- **Xyngari in acne demonstrated statistically significant reductions in lesions counts at 4 weeks versus placebo**

Tolerability and Side Effects

- Current products have various side effects and tolerability issues occurring well before a treatment effect leading to poor overall compliance
- **Xyngari's tolerability profile and comparatively fast onset of action may improve compliance, leading to better patient outcomes**

Application of Xyngari

Sponge is processed into a fine powder and packaged into pouches with a bottle of 3% H_2O_2



Once weekly, patients mix powder with 3% H_2O_2 and massage onto their skin; after 10-15 minutes, the product is washed off

dermata

Xyngari Phase 3 Acne Program: STAR-1 Topline Results Successful

Program Design:

- Two identical studies that will be double-blind, randomized, placebo-controlled, designed to assess the safety, tolerability and efficacy of once weekly application of Xyngari in patients with moderate-to-severe acne
- One long-term extension study

Study Details and Eligibility

- Patients 9 years and older
- Patients must have an IGA baseline score of 3 or 4
- 12-Week study duration
- **Once weekly** application

Endpoints

- Absolute Reduction in Inflammatory Lesion Counts
- Absolute Reduction in Non-inflammatory Lesion Counts
- Investigator Global Assessment (IGA Scale = 0 to 4)
  - Responder classified as 2-Grade reduction and 0 or 1

***Same three primary endpoints as measured in the Phase 2b study**

dermata

STAR-1 Phase 3 Results: Mean Reduction in Inflammatory Lesions



*ITT Population

dermata

STAR-1 Phase 3 Results: Mean Reduction in Noninflammatory Lesions



*ITT Population

dermata

STAR-1 Phase 3 Results: Investigator's Global Assessment



*ITT Population

dermata

STAR-1 Phase 3 – Inflammatory Lesions Change from baseline across studies demonstrate consistent treatment effect

	Phase 2a Lot # 18-M-03 (n=31)	Phase 2b Lot # 19208 (n=91)	STAR-1 Lot #'s 2002496, 497, 498 (n=341)
Baseline[1]	26.0	25.0	25.0
Week 4	-11.7	-11.3	-11.4
Week 8	-14.3	-13.6	-14.7
Week 12	-15.8	-15.6	-16.8

1 – Median Baseline Inflammatory Lesion Count

dermata

dermata

DMT410

Enabling Topical Application of Botulinum Toxin

DMT410 Overview

DMT410's Combination Regimen for Botulinum Toxin

DMT410 is a combination treatment using Xyngari to create millions of microchannels **for topical delivery of botulinum toxin** to the dermis



* Spicules average about 200 µm in length, 10-15 µm in diameter



Sponge mixture creates millions of microchannels in the human skin

Simple Application Process of DMT410

Sponge mixture is massaged into the treatment area:

- **Enhances spicule penetration**
- **Creates microchannels through the stratum corneum**

Sponge mixture is then removed after 10-15 minutes

Botulinum toxin liquid formulation is applied to the skin and massaged into the treatment area, utilizing sponge's newly created microchannels



dermata

Benefits of DMT410 versus Injections for Delivery of Botulinum Toxin

Molecule Size

Injection Limitation

- Botulinum toxin molecules are between 150-900 kDa and are currently injected for clinical efficacy

DMT410 Potential Benefit

- **DMT410 creates microchannels in the skin that allow topical penetration of botulinum toxin into the dermis**

Increased Coverage

Injection Limitation

- Botulinum toxin injections limit the spread over a large surface area

DMT410 Potential Benefit

- **The creation of millions of microchannels allow a uniform topical application of toxin to more easily deliver treatment to a larger surface area**

No Injections Necessary

Injection Limitation

- Current treatments, like hyperhidrosis, require 10-20 injections in each axilla that can be painful for patients

DMT410 Potential Benefit

- **DMT410's topical application had favorable tolerability in hyperhidrosis clinical trial**

Additional Uses

Injection Limitation

- There are multiple aesthetic conditions where botulinum toxin has efficacy, but difficulty of intradermal injections limits commercial opportunity

DMT410 Potential Benefit

- **DMT410's topical delivery could expand the potential indications for botulinum toxin**

dermata

Collaboration with Revance: XYNGARI + DAXXIFY Phase 2a Study in Axillary Hyperhidrosis

Collaboration Design: Dermata and Revance intend to conduct a Phase 2a study in axillary hyperhidrosis with intentions to expand to additional indications in the future

Study Design

- **Patients will receive one application of XYNGARI followed by DAXXIFY/Placebo to one axilla and XYNGARI mixed with DAXXIFY/Placebo to the other axilla**
- Placebo controlled
- 48 (1:1:1:1) adult patients enrolled at 3-5 site in the US
- 16-Week study duration
- **Treatment Arms:**
  - **XYNGARI + DAXXIFY (100U)**
  - **XYNGARI + DAXXIFY (200U)**
  - **XYNGARI + DAXXIFY (300U)**
  - **XYNGARI + Placebo**

Endpoints

- Percent of patients with ≥50% reduction in gravimetrically measured sweat production from baseline
- Percent of patients with gravimetric sweat production of ≤50mg
- Percent change in gravimetric sweat production

dermata

DMT410 Phase 1b: Axillary Hyperhidrosis

Study Design

- Open-label
- 10 adult patients (20 axillae) enrolled at one site in the US
- 4-Week study duration
- **DMT410: One application of sponge powder, followed by one topical application of BOTOX®**

Endpoints

- Percent of patients with ≥50% reduction in gravimetrically measured sweat production from baseline
- Percent of patients with gravimetric sweat production of ≤50mg
- Percent change in gravimetric sweat production

Phase 1b Results: Reduction in Sweat Production

	DMT410 (N=20) Response Rate
Decrease in gravimetric sweat production ≥ 50%	80%
Gravimetric sweat production <50mg	85%
Change in gravimetric sweat production	-75%

dermata

DMT410 Phase 1b: Facial Aesthetics

Study Design

- Open-label
- 10 adult patients received a single, sequential topical application of:
  - **DMT410 + H_2O**
  - **BOTOX ® (64U per label)**
- Patients assessed at Week 4, Week 8, Week 12 and Week 16 post application

Endpoints

- Reduction of:

Glabellar Lines	Forehead Lines	Lateral Canthal Lines
Fine Lines	Pore Size	Sebum Production

- Improvements in:
  - Luminosity and brightness
  - Improvements in Global Aesthetic scale

Key Findings

- Well-tolerated and produced no potential distant spread of toxin events
- Demonstrated improvements in luminosity, brightness, and global aesthetics
- Reduced pore size, sebum production, and fine lines

dermata

DMT410 Phase 1b Aesthetics: Canfield VISIA Image Analysis
Change from Baseline to Month 1

Measure	Forehead		Left Temple		Right Temple	
	Mean Change	Pct Change	Mean Change	Pct Change	Mean Change	Pct Change
Pore Count	-107.5	-12.2%	-14.8	-11.1%	-21.3	-19.0%
Pore Area	-5.2	-16.4%	-1.7	-10.0%	-2.0	-16.5%
Wrinkle Count	-12.2	-11.6%	-3.2	-18.9%	-3.4	-19.0%
Wrinkle Area	-11.7	-7.0%	-4.1	-13.5%	-5.1	-14.1%

dermata

DMT410 Phase 1b Aesthetics: Canfield VISIA Pore Analysis from Baseline to Month 1

Baseline



Visit 4



Subject 013

Data Point	Value
Pore Count	302
Pore FA	0.77

Data Point	Value
Pore Count	100
Pore FA	0.32

dermata

Spongilla Platform: Potential Uses

Xyngari

Acne
- Moderate to Severe – Rx
- Mild to Moderate – OTC

Psoriasis
- Mild to Moderate

Acne Scars

DMT400

DMT410 – Topical delivery of botulinum toxin into the dermis
- Aesthetics
  - reduction of pore size/number,
  - reduction in sebum production
  - reduction of fine lines
  - increase brightness/luminosity
- Acne – Severe to Very Severe
- Acne Scars
- Hyperhidrosis – axillary, palmar, plantar
- Rosacea

DMT420 – Topical delivery of biologic (eg, Mab)
- Psoriasis
- Hidradenitis suppurativa

DTM430 – Topical delivery of HA/dermal filler

dermata

IP Overview

Patent

- Issued:
  - DMT410 – treatment of hyperhidrosis in Japan
  - XYNGARI – treatment of acne in USA
- Accepted:
  - DMT410 – treatment of hyperhidrosis in Australia
- Applications:
  - XYNGARI - sponge as a single entity
    - Treatment of acne
  - DMT410 – sponge plus botulinum toxin
    - Treatment of hyperhidrosis
    - Treatment of aesthetic skin conditions
    - Treatment of acne
  - DMT420 - sponge plus monoclonal antibodies
  - DMT430 – sponge plus dermal fillers

Supply

- Signed an exclusive supply agreement with the largest known supplier of *Spongilla lacustris*
- Favorable COGS

Regulatory

- No clear regulatory pathway for a ”generic” botanical product
- Likely would be required to follow the same pathway as a biosimilar

Trade Secrets

- Proprietary analytical methods
- Proprietary placebo

dermata

Dermata Therapeutics

Transforming Topical Treatment of the Skin